Vireo Growth (VREOF) Non Operating Income (2020 - 2026)
Vireo Growth (VREOF) reported Non Operating Income of -$13.2 million for Q1 2026, down 230.0% on a YoY basis from $10.2 million in Q1 2025, and down 203.72% sequentially from $12.7 million in Q4 2025.
Vireo Growth (VREOF) Non Operating Income (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Non Operating Income data on file, last reported at -$13.2 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 230.0% year-over-year to -$13.2 million; the trailing twelve-month figure through Mar 2026 stood at -$22.3 million (up 17.21% YoY), and the FY2025 full-year result was -$15.9 million, up 47.78% from the prior year.
- Non Operating Income retreated to -$13.2 million in Q1 2026, from $12.7 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $12.7 million in Q4 2025 to a low of -$13.8 million in Q3 2025.
- A 5-year average of -$6.8 million and a median of -$7.6 million in 2022 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income slumped 1505.39% in 2022 and surged 221.01% in 2025, its largest moves.
- Tracing VREOF's Non Operating Income over 5 years: stood at -$8.0 million in 2022, then retreated by 11.68% to -$9.0 million in 2023, then retreated by 17.16% to -$10.5 million in 2024, then surged by 221.01% to $12.7 million in 2025, then sank by 203.72% to -$13.2 million in 2026.
- Business Quant data shows VREOF's Non Operating Income at -$13.2 million in Q1 2026, $12.7 million in Q4 2025, and -$13.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -7.50 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -13.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.20 Mn |
| Dec 31, 2025 | 12.73 Mn |
| Sep 30, 2025 | -13.76 Mn |
| Jun 30, 2025 | -8.06 Mn |
| Mar 31, 2025 | -4.00 Mn |
| Dec 31, 2024 | -10.52 Mn |
| Sep 30, 2024 | -6.39 Mn |
| Jun 30, 2024 | -6.02 Mn |
| Mar 31, 2024 | -7.53 Mn |
| Dec 31, 2023 | -8.98 Mn |
| Sep 30, 2023 | -7.62 Mn |
| Jun 30, 2023 | -4.69 Mn |
| Mar 31, 2023 | -7.11 Mn |
| Dec 31, 2022 | -8.04 Mn |
| Sep 30, 2022 | -7.59 Mn |
| Jun 30, 2022 | -5.45 Mn |
| Mar 31, 2022 | -8.55 Mn |
| Dec 31, 2021 | -3.52 Mn |
| Sep 30, 2021 | -2.18 Mn |
| Jun 30, 2021 | -2.85 Mn |